Journal
PHYSIOLOGICAL REVIEWS
Volume 99, Issue 4, Pages 1763-1817Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/physrev.00022.2018
Keywords
apoptosis; cell death; heart disease; necroptosis; necrosis
Categories
Funding
- National Institutes of Health [R01HL127339, R15HL135726, R01HL116507, R01HL128071, R01 HL130861, R01HL138475]
- Department of Defense [PR151134P1]
- American Heart Association [15PRE25080032, 15CSA26240000, 18SRG34280018]
- Fondation Leducq
- Deutsche Forschungsgemeinschaft [EXC 306]
- Else Kroner-Fresenius Stiftung
Ask authors/readers for more resources
Twelve regulated cell death programs have been described. We review in detail the basic biology of nine including death receptor-mediated apoptosis, death receptor-mediated necrosis (necroptosis), mitochondrial-mediated apoptosis, mitochondrial-mediated necrosis, autophagy-dependent cell death, ferroptosis, pyroptosis, parthanatos, and immunogenic cell death. This is followed by a dissection of the roles of these cell death programs in the major cardiac syndromes: myocardial infarction and heart failure. The most important conclusion relevant to heart disease is that regulated forms of cardiomyocyte death play important roles in both myocardial infarction with reperfusion (ischemia/reperfusion) and heart failure. While a role for apoptosis in ischemia/reperfusion cannot be excluded, regulated forms of necrosis, through both death receptor and mitochondrial pathways, are critical. Ferroptosis and parthanatos are also likely important in ischemia/reperfusion, although it is unclear if these entities are functioning as independent death programs or as amplification mechanisms for necrotic cell death. Pyroptosis may also contribute to ischemia/reperfusion injury, but potentially through effects in non-cardiomyocytes. Cardiomyocyte loss through apoptosis and necrosis is also an important component in the pathogenesis of heart failure and is mediated by both death receptor and mitochondrial signaling. Roles for immunogenic cell death in cardiac disease remain to be defined but merit study in this era of immune checkpoint cancer therapy. Biology-based approaches to inhibit cell death in the various cardiac syndromes are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available